BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31729192)

  • 21. The kinetics of circulating cytokines including IL-6, TNF-alpha, IL-8 and IL-10 following allogeneic hematopoietic stem cell transplantation.
    Min CK; Lee WY; Min DJ; Lee DG; Kim YJ; Park YH; Kim HJ; Lee S; Kim DW; Lee JW; Min WS; Kim CC
    Bone Marrow Transplant; 2001 Nov; 28(10):935-40. PubMed ID: 11753547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in circulating endothelial cells count could become a valuable tool in the diagnostic definition of acute graft-versus-host disease.
    Almici C; Skert C; Verardi R; Di Palma A; Bianchetti A; Neva A; Braga S; Malagola M; Turra A; Marini M; Russo D
    Transplantation; 2014 Oct; 98(7):706-12. PubMed ID: 25119132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease.
    Großekatthöfer M; Güclü ED; Lawitschka A; Matthes-Martin S; Mann G; Minkov M; Peters C; Seidel MG
    Ann Hematol; 2013 Aug; 92(8):1121-8. PubMed ID: 23604429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ferritin as an early marker of graft rejection after allogeneic hematopoietic stem cell transplantation in pediatric patients.
    Döring M; Cabanillas Stanchi KM; Feucht J; Queudeville M; Teltschik HM; Lang P; Feuchtinger T; Handgretinger R; Müller I
    Ann Hematol; 2016 Jan; 95(2):311-23. PubMed ID: 26611853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Significance of ST2 in the Early Diagnosis and Treatment of Graft-Versus-Host Disease--Review].
    Lu RQ; Guo R
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):307-10. PubMed ID: 26913443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (Allo-HCT)?
    Toubai T; Tanaka J; Paczesny S; Shono Y; Reddy P; Imamura M
    Curr Stem Cell Res Ther; 2012 May; 7(3):229-39. PubMed ID: 22023620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide.
    Kanakry CG; Bakoyannis G; Perkins SM; McCurdy SR; Vulic A; Warren EH; Daguindau E; Olmsted T; Mumaw C; Towlerton AMH; Cooke KR; O'Donnell PV; Symons HJ; Paczesny S; Luznik L
    Haematologica; 2017 May; 102(5):932-940. PubMed ID: 28126963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Soluble interleukin-27 receptor alpha is a valuable prognostic biomarker for acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.
    Liu S; Han J; Gong H; Li Y; Bao X; Qi J; Liu H; Chen J; Wu X; Xu Y; Ma S; Wu D
    Sci Rep; 2018 Jul; 8(1):10328. PubMed ID: 29985424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic prediction of relapse in recipients of allogeneic haematopoietic stem cell transplantation.
    Ritari J; Hyvärinen K; Koskela S; Itälä-Remes M; Niittyvuopio R; Nihtinen A; Salmenniemi U; Putkonen M; Volin L; Kwan T; Pastinen T; Partanen J
    Leukemia; 2019 Jan; 33(1):240-248. PubMed ID: 30089915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignancies.
    Beckerson J; Szydlo RM; Hickson M; Mactier CE; Innes AJ; Gabriel IH; Palanicawandar R; Kanfer EJ; Macdonald DH; Milojkovic D; Rahemtulla A; Chaidos A; Karadimitris A; Olavarria E; Apperley JF; Pavlu J
    Clin Nutr; 2019 Apr; 38(2):738-744. PubMed ID: 29650256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
    Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
    Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tear Cytokines as Biomarkers for Chronic Graft-versus-Host Disease.
    Jung JW; Han SJ; Song MK; Kim TI; Kim EK; Min YH; Cheong JW; Seo KY
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2079-2085. PubMed ID: 26303101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD.
    Major-Monfried H; Renteria AS; Pawarode A; Reddy P; Ayuk F; Holler E; Efebera YA; Hogan WJ; Wölfl M; Qayed M; Hexner EO; Wudhikarn K; Ordemann R; Young R; Shah J; Hartwell MJ; Chaudhry MS; Aziz M; Etra A; Yanik GA; Kröger N; Weber D; Chen YB; Nakamura R; Rösler W; Kitko CL; Harris AC; Pulsipher M; Reshef R; Kowalyk S; Morales G; Torres I; Özbek U; Ferrara JLM; Levine JE
    Blood; 2018 Jun; 131(25):2846-2855. PubMed ID: 29545329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma-based protein biomarkers can predict the risk of acute graft-versus-host disease and non-relapse mortality in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Shin J; Dan K; Han D; Kim JW; Kim KK; Koh Y; Shin DY; Hong J; Yoon SS; Park S; Song SH; Kim I
    Blood Cells Mol Dis; 2019 Feb; 74():5-12. PubMed ID: 30344086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association Between Low Plasma Level of Citrulline Before Allogeneic Hematopoietic Cell Transplantation and Severe Gastrointestinal Graft vs Host Disease.
    Hueso T; Gauthier J; Joncquel Chevalier-Curt M; Magro L; Coiteux V; Dulery R; Carpentier B; Labreuche J; Damaj G; Yakoub-Agha I; Seguy D
    Clin Gastroenterol Hepatol; 2018 Jun; 16(6):908-917.e2. PubMed ID: 29258901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of fecal calprotectin as biomarker of gastrointestinal GVHD after allogeneic stem cell transplantation.
    Chiusolo P; Metafuni E; Giammarco S; Bellesi S; Piccirillo N; Fanali C; Castagnola M; Zuppi C; De Michele T; Leone G; Sica S
    Blood; 2012 Nov; 120(22):4443-4. PubMed ID: 23175663
    [No Abstract]   [Full Text] [Related]  

  • 37. Level of vascular endothelial growth factor predicts both relapse and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.
    Moiseev IS; Lapin SV; Surkova EA; Lerner MY; Vavilov VN; Afanasyev BV
    Biol Blood Marrow Transplant; 2013 Dec; 19(12):1677-82. PubMed ID: 24035780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
    Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
    Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment.
    McDonald GB; Tabellini L; Storer BE; Lawler RL; Martin PJ; Hansen JA
    Blood; 2015 Jul; 126(1):113-20. PubMed ID: 25987657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in understanding the pathogenesis of graft-versus-host disease.
    Magenau J; Runaas L; Reddy P
    Br J Haematol; 2016 Apr; 173(2):190-205. PubMed ID: 27019012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.